In this special edition of the View, Dr. Eagle summarizes the top science that will be presented at AHA 2023 from November 11 to November 13 in Philadelphia.  

 Dr. Eagle shares some of the trials that have captured attention, including:  SELECT, that investigates semaglutide and cardiovascular outcomes in non-diabetic patients who are overweight or obese;  ORBITA-2, a randomized trial that evaluates PCI for Stable Angina; DAPA-MI, a registry-based randomized trial examining the effects of Dapagliflozin in patients with acute myocardial infarction without diabetes; the REPRIEVE study that investigates the effects of pitavastatin on coronary artery disease and inflammatory biomarkers in individuals with HIV; the HEART-1 trial that discusses the safety and pharmacodynamic effects of VERVE-101, an investigational DNA base editing medicine; and the ESPIRIT trial investigating the effects of intensive blood pressure lowering treatment in reducing the risk of cardiovascular events.

These trials hold significant promise for advancing the field of cardiology.  Our team looks forward to reviewing the results at AHA 2023.   

There will be daily updates giving more details on these trials and more. 

Subscribe to Eagle’s Eye View